Related references
Note: Only part of the references are listed.Hepatoprotective Effect of a New FFAR1 Agonist-N-Alkylated Isobornylamine
Darya Pon'kina et al.
MOLECULES (2023)
Diabetic nephropathy: Focusing on pathological signals, clinical treatment, and dietary regulation
Qichao Hu et al.
BIOMEDICINE & PHARMACOTHERAPY (2023)
Synthesis, in vitro evaluation, and computational simulations studies of 1,2,3-triazole analogues as DPP-4 inhibitors
Duy-Viet Vo et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2021)
Design, synthesis and bioactivity evaluation of thiazolidinedione derivatives as partial agonists targeting PPARγ
Juan Sun et al.
BIOORGANIC CHEMISTRY (2021)
Design, synthesis and biological evaluation of novel 5-(imidazolyl-methyl) thiazolidinediones as antidiabetic agents
Neda Shakour et al.
BIOORGANIC CHEMISTRY (2021)
GPR120/FFAR4 Pharmacology: Focus on Agonists in Type 2 Diabetes Mellitus Drug Discovery
Gabriele Carullo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
A new synthetic dual agonist of GPR120/GPR40 induces GLP-1 secretion and improves glucose homeostasis in mice
Gianluca Bianchini et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
FFAR1/GPR40: One target, different binding sites, many agonists, no drugs, but a continuous and unprofitable tug-of-war between ligand lipophilicity, activity, and toxicity
Paolo Governa et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)
Design, synthesis and biological evaluation of glycolamide, glycinamide, and β-amino carbonyl 1,2,4-triazole derivatives as DPP-4 inhibitors
Mao-Tsu Fuh et al.
BIOORGANIC CHEMISTRY (2021)
Synthesis, molecular docking, dynamic simulation and pharmacological characterization of potent multifunctional agent (dual GPR40-PPARγ agonist) for the treatment of experimental type 2 diabetes
Sergio Hidalgo-Figueroa et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2021)
Diacylglycerol-evoked activation of PKC and PKD isoforms in regulation of glucose and lipid metabolism: a review
Katarzyna Kolczynska et al.
LIPIDS IN HEALTH AND DISEASE (2020)
Exploring bulky natural and natural -like periphery in the design of p-(benzyloxy)phenylpropionic acid agonists of free fatty acid receptor 1 (GPR40)
Sergey O. Kuranov et al.
BIOORGANIC CHEMISTRY (2020)
Pathophysiology of Type 2 Diabetes Mellitus
Unai Galicia-Garcia et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Bornyl Derivatives of p-(Benzyloxy)Phenylpropionic Acid: In Vivo Evaluation of Antidiabetic Activity
Sergey Kuranov et al.
PHARMACEUTICALS (2020)
FFA1 (GPR40) Receptor Agonists Based on Phenylpropanoic Acid as Hypoglycemic Agents: Structure-Activity Relationship
S. O. Kuranov et al.
RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY (2020)
Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends
Moien Abdul Basith Khan et al.
JOURNAL OF EPIDEMIOLOGY AND GLOBAL HEALTH (2020)
Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition
Pouya Saeedi et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
The integrative biology of type 2 diabetes
Michael Roden et al.
NATURE (2019)
Design, synthesis and biological evaluation of (2S, 3R, 4R, 5S, 6R)-5-fluoro-6-(hydroxymethyl)-2-aryltetrahydro-2H-pyran-3,4-diols as potent and orally active SGLT dual inhibitors
Guozhang Xu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
Design and Synthesis of Novel, Selective GPR40 AgoPAMs
Christopher W. Plummer et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Conversion of glycals into vicinal-1,2-diazides and 1,2-(or 2,1)-azidoacetates using hypervalent iodine reagents and Me3SiN3. Application in the synthesis of N-glycopeptides, pseudo-trisaccharides and an iminosugar
Ande Chennaiah et al.
RSC ADVANCES (2017)
Potential of the chlorogenic acid as multitarget agent: Insulin-secretagogue and PPAR α/γ dual agonist
Maetzin Becerra Sanchez et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)
Chafiq Hamdouchi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Synthesis of novel L-rhamnose derived acyclic C-nucleosides with substituted 1,2,3-triazole core as potent sodium-glucose co-transporter (SGLT) inhibitors
Siddamal Reddy Putapatri et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
3-Phenylpropanoic Acid- Based Phosphotyrosine ( pTyr) Mimetics: Hit Evolution to a Novel Orally Active Protein Tyrosine Phosphatase 1B ( PTP1B) Inhibitor
Yan-Bo Tang et al.
CHEMMEDCHEM (2014)
Modulating GPR40: therapeutic promise and potential in diabetes
Vincent Poitout et al.
DRUG DISCOVERY TODAY (2013)
Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist
Sean P. Brown et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
Rational Targeting of Peroxisome Proliferating Activated Receptor Subtypes
D. K. Nevin et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Synthesis of novel PPAR alpha/gamma dual agonists as potential drugs for the treatment of the metabolic syndrome and diabetes type II designed using a new de novo design program PROTOBUILD
Yushma Bhurruth-Alcor et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2011)
Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion
Sara Edfalk et al.
DIABETES (2008)
Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK
Zhe Cheng et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2006)
Analysis of the critical structural determinant(s) of species-selective peroxisome proliferator-activated receptor alpha (PPARα)-activation by phenylpropanoic acid-type PPARα agonists
H Miyachi et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids
CP Briscoe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Effects of berberine on glucose metabolism in vitro
J Yin et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2002)
Share Paper
